Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Omzotirome - Torrent Pharmaceuticals

Next Previous
Drug Profile

Omzotirome - Torrent Pharmaceuticals

Alternative Names: T2-mimetic; TRC-150094

Latest Information Update: 22 Mar 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Torrent Pharmaceuticals
  • Class Antihyperglycaemics; Antihypertensives; Indenes; Obesity therapies; Peptidomimetics; Propionic acids; Pyrazoles
  • Mechanism of Action Thyroid hormone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Diabetes mellitus; Dyslipidaemias; Hypertension
  • No development reported Metabolic syndrome

Most Recent Events

  • 22 Mar 2022 TRC 150094 is still in phase III trials for Diabetes mellitus, Dyslipidaemias and Hypertension (Adjunctive treatment) in India, Philippines and Brazil (PO) (Torrent Pharmaceuticals pipeline, March 2022) (NCT03254446)
  • 22 Mar 2022 No development reported - Phase-III for Diabetes mellitus (Adjunctive treatment) in Thailand, Sri Lanka (PO)
  • 22 Mar 2022 No development reported - Phase-III for Dyslipidaemias (Adjunctive treatment) in Sri Lanka, Thailand (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top